Legend Biotech Corporation filed a Form 6-K on November 4, 2026, announcing seven presentations at the 68th American Society of Hematology Annual Meeting, including five focused on CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for multiple myeloma.

Key Highlights

  • Seven total presentations: The company disclosed two oral presentations, two poster presentations, and one ePublication on CARVYKTI, plus two additional poster presentations on other pipeline candidates.
  • Conference dates and location: The 68th ASH Annual Meeting is scheduled for December 12-15, 2026, in New Orleans, LA, according to the filing.
  • CARVYKTI focus: The five CARVYKTI-related presentations address its use in multiple myeloma, the filing states.
  • LUCAR-G39D presentation: The company disclosed a poster on LUCAR-G39D, described as an anti-CD20/CD19 dual-CAR allogeneic gamma delta T-cell therapy in relapsed or refractory B-cell non-Hodgkin lymphoma.
  • LB2501 presentation: The filing also announced a poster on LB2501, described as the company's "first-in-human in vivo CD19/CD20 dual targeting CAR-T therapy," being evaluated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
  • Signed by CEO: The filing was signed by Ingrid Zhang, Chief Executive Officer, on November 3, 2026.

Legend Biotech's December 2026 ASH Disclosure: CARVYKTI and Pipeline Data

Legend Biotech Corporation (NASDAQ:LEGN) disclosed via a Form 6-K, dated November 4, 2026, that it will present clinical and research data across seven sessions at the 68th ASH Annual Meeting. According to the filing, five of those presentations pertain to CARVYKTI (ciltacabtagene autoleucel; cilta-cel), the company's CAR-T therapy for multiple myeloma, comprising two oral presentations, two poster presentations, and one ePublication.

Beyond CARVYKTI, the company disclosed two additional poster presentations covering earlier-stage pipeline assets. The first covers LUCAR-G39D, which the filing describes as an anti-CD20/CD19 dual-CAR allogeneic gamma delta T-cell therapy studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The second covers LB2501, described in the filing as the company's "first-in-human in vivo CD19/CD20 dual targeting CAR-T therapy," also being evaluated in relapsed or refractory B-cell non-Hodgkin lymphoma.

The press release containing full details was attached to the filing as Exhibit 99.1. The company also noted that the Form 6-K, including exhibits, is incorporated by reference into its registration statements on Form F-3 (Nos. 333-278050 and 333-257625) and Form S-8 (Nos. 333-299349, 333-239478 and 333-283217), to the extent not superseded by subsequently filed documents or reports.

What Was Disclosed

Legend Biotech filed a Form 6-K on November 4, 2026, announcing seven presentations at the 68th ASH Annual Meeting in December 2026, covering CARVYKTI for multiple myeloma and two additional pipeline therapies, LUCAR-G39D and LB2501, for B-cell non-Hodgkin lymphoma.